Literature DB >> 3582293

Intradose and circadian variation in circulating carbamazepine and its epoxide in epileptic patients: a consequence of autoinduction of metabolism.

G J Macphee, E Butler, M J Brodie.   

Abstract

Total and free carbamazepine (CBZ), and CBZ 10,11 epoxide (CBZ-E) concentrations were measured over 24 h in 19 patients receiving CBZ 400 mg b.i.d. either as monotherapy (n = 13) or combined with another anticonvulsant (n = 6). Differences in CBZ and CBZ-E disposition between day and night dosing were minor. Mean plasma CBZ concentrations were higher and CBZ-E/CBZ ratios were lower in the monotherapy patients. Variations in total and free plasma CBZ levels were comparable in the monotherapy and polypharmacy groups. Peak free and total CBZ concentrations coincided at approximately 4 h postdose. Free CBZ levels correlated significantly with total in each patient. The extent of variation in total plasma CBZ concentration during 24 h correlated significantly with antipyrine clearance in the monotherapy group. Circadian rhythms are unlikely to influence CBZ disposition to a clinically relevant extent. Measurement of peak and trough CBZ concentrations should improve the value of therapeutic drug monitoring. The diurnal variation in CBZ concentration appears related to the degree of autoinduction of metabolism and is substantial enough to warrant the development of a slow-release preparation of the drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3582293     DOI: 10.1111/j.1528-1157.1987.tb04220.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

1.  Simulated fluctuations in plasma drug concentrations for patients receiving oxcarbazepine or carbamazepine extended-release capsules.

Authors:  Alaa Ahmad; William R Garnett
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

Review 2.  Tolerability and Safety of Commonly Used Antiepileptic Drugs in Adolescents and Adults: A Clinician's Overview.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-02       Impact factor: 5.749

Review 3.  Sodium Channel Blockers in the Treatment of Epilepsy.

Authors:  Martin J Brodie
Journal:  CNS Drugs       Date:  2017-07       Impact factor: 5.749

4.  Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects.

Authors:  J G Larkin; P J McKee; G Forrest; G H Beastall; B K Park; J I Lowrie; P Lloyd; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

5.  Rapid tolerance to acute psychomotor impairment with carbamazepine in epileptic patients.

Authors:  J G Larkin; P J McKee; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

7.  Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.

Authors:  P J McKee; J Blacklaw; E Butler; R A Gillham; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

8.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

Review 9.  Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.

Authors:  S M Grant; D Faulds
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

10.  A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients.

Authors:  P J McKee; J Blacklaw; G Forrest; R A Gillham; S M Walker; D Connelly; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1994-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.